186 related articles for article (PubMed ID: 32462079)
1. Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts.
Ang WX; Ng YY; Xiao L; Chen C; Li Z; Chi Z; Tay JC; Tan WK; Zeng J; Toh HC; Wang S
Mol Ther Oncolytics; 2020 Jun; 17():421-430. PubMed ID: 32462079
[TBL] [Abstract][Full Text] [Related]
2. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
3. Vγ9Vδ2 T cells expressing a BCMA-Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth.
Zhang X; Ng YY; Du Z; Li Z; Chen C; Xiao L; Chng WJ; Wang S
PLoS One; 2022; 17(6):e0267475. PubMed ID: 35709135
[TBL] [Abstract][Full Text] [Related]
4. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
5. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
[TBL] [Abstract][Full Text] [Related]
6. MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.
Zhai X; You F; Xiang S; Jiang L; Chen D; Li Y; Fan S; Han Z; Zhang T; An G; Zhang B; Chen Y; Meng H; Yang L
Am J Cancer Res; 2021; 11(1):79-91. PubMed ID: 33520361
[TBL] [Abstract][Full Text] [Related]
7. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
[TBL] [Abstract][Full Text] [Related]
8. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
[TBL] [Abstract][Full Text] [Related]
9. Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR.
Li Z; Chi Z; Ang WX; Chen C; Tay JC; Ng YY; Xu X; Wang J; Zhu J; Wang S
Immunotherapy; 2020 Jul; 12(10):733-748. PubMed ID: 32571133
[No Abstract] [Full Text] [Related]
10. Role of NKG2D and its ligands in the anti-infectious activity of Vγ9Vδ2 T cells against intracellular bacteria.
Bessoles S; Ni M; Garcia-Jimenez S; Sanchez F; Lafont V
Eur J Immunol; 2011 Jun; 41(6):1619-28. PubMed ID: 21469127
[TBL] [Abstract][Full Text] [Related]
11. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
[No Abstract] [Full Text] [Related]
12. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment.
Tao K; He M; Tao F; Xu G; Ye M; Zheng Y; Li Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):815-827. PubMed ID: 30132099
[TBL] [Abstract][Full Text] [Related]
13. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
[TBL] [Abstract][Full Text] [Related]
14. Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion.
He C; Zhou Y; Li Z; Farooq MA; Ajmal I; Zhang H; Zhang L; Tao L; Yao J; Du B; Liu M; Jiang W
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32698361
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo.
Deng X; Gao F; Li N; Li Q; Zhou Y; Yang T; Cai Z; Du P; Chen F; Cai J
Am J Cancer Res; 2019; 9(5):945-958. PubMed ID: 31218103
[TBL] [Abstract][Full Text] [Related]
16. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro.
Zarei M; Abdoli S; Farazmandfar T; Shahbazi M
Heliyon; 2023 Oct; 9(10):e20460. PubMed ID: 37790973
[TBL] [Abstract][Full Text] [Related]
18. DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells.
Zhao R; Cheng L; Jiang Z; Wei X; Li B; Wu Q; Wang S; Lin S; Long Y; Zhang X; Wu Y; Du X; Pei D; Liu P; Li Y; Cui S; Yao Y; Li P
Oncoimmunology; 2019; 8(1):e1509173. PubMed ID: 30546945
[TBL] [Abstract][Full Text] [Related]
19. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
20. Suppression of 4.1R enhances the potency of NKG2D-CAR T cells against pancreatic carcinoma via activating ERK signaling pathway.
Gao Y; Lin H; Guo D; Cheng S; Zhou Y; Zhang L; Yao J; Farooq MA; Ajmal I; Duan Y; He C; Tao L; Wu S; Liu M; Jiang W
Oncogenesis; 2021 Sep; 10(9):62. PubMed ID: 34548478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
